Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

Feb 7, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the extraction of the core software supporting the operations of Kremers Urban Pharmaceuticals, Inc. (KU) from UCB Pharma....

More
Feb 1, 2017
--Net Sales Increased 35% to Approximately $171 Million; Company Continues to Expect Strong Fiscal Year--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 second quarter ended December 31, 2016. The company completed the acquisition of Kremers Urban...

More
Jan 25, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 second quarter on Wednesday, February 1, 2017, after the market closes. Lannett...

More
Jan 23, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $75 million payment against its existing revolving credit facility. "This payment is consistent with our...

More
Jan 3, 2017
--Company May Be Eligible for 180 Days of Generic Drug Marketing Exclusivity--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval last week from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lopinavir...

More
Dec 19, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate...

More
Dec 7, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 a.m....

More
Nov 30, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) granted the company a 90-day extension to submit documentation concerning its Methylphenidate...

More
Nov 28, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Metaxalone Tablets...

More
Nov 14, 2016

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products